Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression

Milad Ashrafizadeh, Sepideh Mirzaei, Mohammad Hossein Gholami, Farid Hashemi, Amirhossein Zabolian, Mehdi Raei, Kiavash Hushmandi, Ali Zarrabi, Nicolas H. Voelcker, Amir Reza Aref, Michael R. Hamblin, Rajender S. Varma, Saeed Samarghandian, I. J. Arostegi, M. Alzola, Alan Prem Kumar, Vijay Kumar Thakur, Noushin Nabavi, Pooyan Makvandi, Franklin R. TayGorka Orive

Research output: Contribution to journalReview ArticleResearchpeer-review

124 Citations (Scopus)

Abstract

An important motivation for the use of nanomaterials and nanoarchitectures in cancer therapy emanates from the widespread emergence of drug resistance. Although doxorubicin (DOX) induces cell cycle arrest and DNA damage by suppressing topoisomerase activity, resistance to DOX has severely restricted its anti-cancer potential. Hyaluronic acid (HA) has been extensively utilized for synthesizing nanoparticles as it interacts with CD44 expressed on the surface of cancer cells. Cancer cells can take up HA-modified nanoparticles through receptor-mediated endocytosis. Various types of nanostructures such as carbon nanomaterials, lipid nanoparticles and polymeric nanocarriers have been modified with HA to enhance the delivery of DOX to cancer cells. Hyaluronic acid-based advanced materials provide a platform for the co-delivery of genes and drugs along with DOX to enhance the efficacy of anti-cancer therapy and overcome chemoresistance. In the present review, the potential methods and application of HA-modified nanostructures for DOX delivery in anti-cancer therapy are discussed.

Original languageEnglish
Article number118491
Number of pages21
JournalCarbohydrate Polymers
Volume272
DOIs
Publication statusPublished - 15 Nov 2021

Keywords

  • CD44
  • Doxorubicin
  • Drug resistance
  • Endocytosis
  • Hyaluronic acid
  • Nanodelivery system
  • Theranostic

Cite this